Analysts Conflicted on These Healthcare Names: Agilon Health (AGL), AN2 Therapeutics, Inc. (ANTX) and Alcon (ALC)
Needham Maintains Alcon(ALC.US) With Buy Rating, Raises Target Price to $107
BTIG Maintains Alcon(ALC.US) With Buy Rating, Raises Target Price to $102
A Quick Look at Today's Ratings for Alcon(ALC.US), With a Forecast Between $91.84 to $106
Alcon Analyst Ratings
Alcon's Strong Q4 Performance and Market Share Gains Reinforce Buy Rating Despite Lower 2025 Guidance
Stifel Maintains Alcon(ALC.US) With Buy Rating, Maintains Target Price $100
Alcon (ALC) Receives a Hold From Kepler Capital
Wells Fargo Maintains Alcon(ALC.US) With Buy Rating, Maintains Target Price $105
Alcon Is Maintained at Overweight by Keybanc
Alcon Analyst Ratings
Needham Maintains Alcon(ALC.US) With Buy Rating, Cuts Target Price to $106
KeyBanc Maintains Alcon(ALC.US) With Buy Rating, Cuts Target Price to $105
Alcon's Resilient Growth Prospects Justify Buy Rating Despite Currency Headwinds
UBS Maintains Alcon(ALC.US) With Buy Rating, Cuts Target Price to $103.86
Berenberg Bank Maintains Alcon(ALC.US) With Buy Rating, Cuts Target Price to $101.94
Berenberg Bank Reaffirms Their Buy Rating on Alcon (ALC)
Redburn Atlantic Upgrades Alcon(ALC.US) to Buy Rating, Raises Target Price to $102.3
Alcon Upgraded to Buy From Neutral at Redburn Atlantic
Stifel Maintains Alcon(ALC.US) With Buy Rating, Announces Target Price $100